Foundation Medicine, shared on LinkedIn:
“Rapid oral presentations at ESMO 2026 highlight new insights in prostate cancer.
Researchers found that patients with metastatic castration-resistant prostate cancer (mCRPC) and clonal hematopoiesis alterations in homologous recombination repair genes appeared not to benefit from PARP inhibitor therapy.
Using data from the phase 3 TALAPRO-3 study, researchers also evaluated ctDNA tumor fraction as a prognostic biomarker in patients with HRR gene-mutated castration-sensitive prostate cancer.
Meet the Foundation Medicine team at Booth 1030, Hall 10, to learn more.”
Other articles about Prostate Cancer on OncoDaily.